The online home of Neurology Reviews

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Evaluating the impact of new pediatric brain tumor classifications

Publish date:: October 26, 2020

Key clinical point: Molecular characterization of pediatric neuronal/glioneuronal tumors has improved in recent years.

Major finding: Molecular characterization provides additional diagnostic and treatment targets.

Study details: Review of multiple studies informing updated World Health Organization classifications.

Disclosures: Dr. Jones has no relevant financial relationships to disclose.

Citation:

Jones DTW et al. CNS-ICNA 2020, Symposium: Neuro-oncology.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Neuro-oncology

Evaluating the impact of new pediatric brain tumor classifications,

WHO-defined IDH molecular subgroups predict adjuvant chemotherapy benefits in low-grade glioma,

QoL Good for MGMT-Methylated Glioblastoma Patients With Lomustine-Temozolide,

Tandem Transplants Provide EFS Edge in Pediatric Neuroblastoma,

Treatment for Pediatric Low-Grade Glioma Associated With Poor Cognitive Outcomes,